Rachel Ann Elliott

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4143406/publications.pdf

Version: 2024-02-01

78 papers 3,282 citations

28 h-index 55 g-index

82 all docs 82 docs citations

82 times ranked 4839 citing authors

#	Article	IF	Citations
1	Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial. Thorax, 2022, 77, 461-469.	5.6	27
2	Does coprescribing nonsteroidal antiâ€inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?. British Journal of Clinical Pharmacology, 2022, 88, 4789-4811.	2.4	8
3	Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Quality and Safety, 2021, 30, 96-105.	3.7	161
4	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. European Journal of Health Economics, 2021, 22, 505-518.	2.8	16
5	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€illness analysis. Liver International, 2021, 41, 1227-1242.	3.9	76
6	A randomized, controlled proof-of-concept trial evaluating durable effects of memory flexibility training (MemFlex) on autobiographical memory distortions and on relapse of recurrent major depressive disorder over 12 months. Behaviour Research and Therapy, 2021, 140, 103835.	3.1	3
7	Flash glucose monitoring with the FreeStyle Libre 2 compared with self-monitoring of blood glucose in suboptimally controlled type 1 diabetes: the FLASH-UK randomised controlled trial protocol. BMJ Open, 2021, 11, e050713.	1.9	7
8	An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT. Programme Grants for Applied Research, 2021, 9, 1-146.	1.0	6
9	Impact of an intervention to support hearing and vision in dementia: The SENSEâ€Cog Field Trial. International Journal of Geriatric Psychiatry, 2020, 35, 348-357.	2.7	41
10	The impact of statin discontinuation and restarting rates on the optimal time to initiate statins and on the number of cardiovascular events prevented. Pharmacoepidemiology and Drug Safety, 2020, 29, 644-652.	1.9	1
11	Lessons from the failure of implementing the †Better Care Better Value' prescribing indicator for renin†"angiotensin system drugs in England: a qualitative study of general practitioners' perceptions using behavioural change framework. BMJ Open, 2020, 10, e035910.	1.9	3
12	A psychological intervention for suicide applied to non-affective psychosis: the CARMS (Cognitive) Tj ETQq0 0 0 20, 306.	rgBT /Over 2.6	rlock 10 Tf 50 14
13	Cost-effectiveness of pain management services for chronic low back pain: a systematic review of published studies. BMC Health Services Research, 2020, 20, 194.	2.2	11
14	†New Medicine Service': supporting adherence in people starting a new medication for a long-term condition: 26-week follow-up of a pragmatic randomised controlled trial. BMJ Quality and Safety, 2020, 29, 286-295.	3.7	26
15	Feasibility of an Intervention to Support Hearing and Vision in Dementia: The SENSE og Field Trial. Journal of the American Geriatrics Society, 2019, 67, 1472-1477.	2.6	22
16	Clinical and economic implications of therapeutic switching of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors. Journal of Hypertension, 2019, 37, 1285-1293.	0.5	3
17	â€`I expected just to walk in, get my tablets and then walk out': on framing new community pharmacy services in the English healthcare system. Sociology of Health and Illness, 2018, 40, 1019-1036.	2.1	22
18	Quantifying the Relationship between Capability and Health in Older People: Can't Map, Won't Map. Medical Decision Making, 2018, 38, 79-94.	2.4	9

#	Article	IF	Citations
19	The HARMONIC trial: study protocol for a randomised controlled feasibility trial of Shaping Healthy Minds—a modular transdiagnostic intervention for mood, stressor-related and anxiety disorders in adults. BMJ Open, 2018, 8, e024546.	1.9	18
20	Reduction of Laboratory Utilization in the Intensive Care Unit. Journal of Intensive Care Medicine, 2017, 32, 500-507.	2.8	20
21	Exploring factors associated with patients' adherence to antihypertensive drugs among people with primary hypertension in the United Kingdom. Journal of Hypertension, 2017, 35, 1881-1890.	0.5	12
22	Biosimilar uptake by British local formularies: a cross sectional study. International Journal of Clinical Pharmacy, 2017, 39, 1055-1060.	2.1	7
23	Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice. Pharmacoeconomics, 2017, 35, 1237-1255.	3.3	36
24	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open, 2017, 7, e015659.	1.9	50
25	Quantifying the origin and distribution of intracluster Light in a Fornax-Like Cluster. Monthly Notices of the Royal Astronomical Society, 2017, 467, 4501-4513.	4.4	7
26	Describing the characteristics, treatment pathways, outcomes, and costs of people with persistent noncancer pain managed by community pain clinics and generating an indicative estimate of cost-effectiveness: feasibility study protocol. Journal of Multidisciplinary Healthcare, 2016, 9, 237.	2.7	2
27	Supporting adherence for people starting a new medication for a long-term condition through community pharmacies: a pragmatic randomised controlled trial of the New Medicine Service. BMJ Quality and Safety, 2016, 25, 747-758.	3.7	73
28	Examination of England's New Medicine Service (NMS) of complex health care interventions in community pharmacy. Research in Social and Administrative Pharmacy, 2016, 12, 966-989.	3.0	38
29	Pastoral power in the community pharmacy: A Foucauldian analysis of services to promote patient adherence to new medicine use. Social Science and Medicine, 2016, 148, 123-130.	3.8	29
30	The impact of the †Better Care Better Value†prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. BMC Health Services Research, 2015, 15, 367.	2.2	12
31	Cost-Effectiveness of a Specialist Geriatric Medical Intervention for Frail Older People Discharged from Acute Medical Units: Economic Evaluation in a Two-Centre Randomised Controlled Trial (AMIGOS). PLoS ONE, 2015, 10, e0121340.	2.5	15
32	Economic Evaluation of a General Hospital Unit for Older People with Delirium and Dementia (TEAM) Tj ETQq0 0	0 <u>15</u> BT /O	verlock 10 Tf
33	developmental work and randomised controlled trial of a specialist geriatric medical intervention for high-risk older people; cohort study of older people with mental health problems admitted to hospital, developmental work and randomised controlled trial of a specialist medical and mental health unit for general hospital patients with delirium and dementia; and cohort study of residents	1.0	7
34	of care homes and interviews. Programme Grants for Applied Research, 2015, 3, 1-410. Identifying patient-level health and social care costs for older adults discharged from acute medical units in England. Age and Ageing, 2014, 43, 703-707.	1.6	17
35	Health status of UK care home residents: a cohort study. Age and Ageing, 2014, 43, 97-103.	1.6	278
36	The economics of medicines optimization: policy developments, remaining challenges and research priorities. British Medical Bulletin, 2014, 111, 45-61.	6.9	10

#	Article	IF	CITATIONS
37	The Cost-Effectiveness of a Pharmacogenetic Test: A Trial-Based Evaluation of TPMT Genotyping for Azathioprine. Value in Health, 2014, 17, 22-33.	0.3	71
38	A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions. Pharmacoeconomics, 2014, 32, 1185-1199.	3.3	31
39	The direct medical costs of epilepsy in children and young people: A population-based study of health resource utilisation. Epilepsy Research, 2014, 108, 576-586.	1.6	15
40	Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER). Pharmacoeconomics, 2014, 32, 573-590.	3.3	36
41	Research into practice: safe prescribing. British Journal of General Practice, 2014, 64, 259-261.	1.4	3
42	Improving adherence needs a multipronged approach. The Prescriber, 2014, 25, 49-51.	0.3	0
43	A Systematic Review of Utility Values for Chemotherapy-Related Adverse Events. Pharmacoeconomics, 2013, 31, 277-288.	3.3	41
44	Protocol for the New Medicine Service Study: a randomized controlled trial and economic evaluation with qualitative appraisal comparing the effectiveness and cost effectiveness of the New Medicine Service in community pharmacies in England. Trials, 2013, 14, 411.	1.6	21
45	Nonadherence to medicines: the scale of the problem. The Prescriber, 2013, 24, 47-50.	0.3	8
46	The Identification of Seniors at Risk (ISAR) score to predict clinical outcomes and health service costs in older people discharged from UK acute medical units. Age and Ageing, 2013, 42, 747-753.	1.6	73
47	A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet, The, 2012, 379, 1310-1319.	13.7	330
48	Valuing pharmacogenetic testing services: A comparison of patients' and health care professionals' preferences. Value in Health, 2011, 14, 121-134.	0.3	58
49	13. "Have You Had That?―Control and Responsibility in Medication Adherence. Journal of Adolescent Health, 2011, 48, S24-S24.	2.5	0
50	A Systematic Review of Adherence-Enhancing Interventions in Adolescents Taking Long-term Medicines. Journal of Adolescent Health, 2011, 49, 455-466.	2.5	43
51	Variation in the management of PONV and pain in day case surgery: implications for evidence based practice. International Journal of Pharmacy Practice, 2011, 9, 16-16.	0.6	0
52	Obtaining accurate patient-specific perioperative anaesthetic costs in orthopaedic anaesthesia. International Journal of Pharmacy Practice, 2011, 9, 37-37.	0.6	0
53	Regional anaesthetic practice in orthopaedic surgery. International Journal of Pharmacy Practice, 2011, 10, R25-R25.	0.6	0
54	Patient perceptions of treatment and illness when prescribed multiple medicines for co-morbid type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2011, 4, 127.	2.4	15

#	Article	IF	CITATIONS
55	A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics, 2011, 12, 815-826.	1.3	69
56	Acute medical unit comprehensive geriatric assessment intervention study (AMIGOS). Trials, 2011, 12, 200.	1.6	12
57	Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ: British Medical Journal, 2011, 342, d108-d108.	2.3	211
58	Using discrete choice experiments to value preferences for pharmacy services. International Journal of Pharmacy Practice, 2010, 13, 9-20.	0.6	16
59	An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?. European Journal of Health Economics, 2010, 11, 57-66.	2.8	32
60	Glycopeptide vs. Non-Glycopeptide Antibiotics for Prophylaxis of Surgical Site Infections: A Systematic Review. Surgical Infections, 2010, 11, 455-462.	1.4	25
61	Non-adherence to medicines: Not solved but solvable. Journal of Health Services Research and Policy, 2009, 14, 58-61.	1.7	45
62	Protocol for the PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices. Trials, 2009, 10, 28.	1.6	38
63	Understanding Medication Compliance and Persistence from an Economics Perspective. Value in Health, 2008, 11, 600-610.	0.3	53
64	Poor Adherence to Medication in AdultsÂwithÂRheumatoid Arthritis. Disease Management and Health Outcomes, 2008, 16, 13-29.	0.4	43
65	Is QUM an Efficient Use of Healthcare Resources?. Journal of Pharmacy Practice and Research, 2008, 38, 172-172.	0.8	2
66	Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics, 2007, 8, 1511-1519.	1.3	99
67	A comparison of parents and pediatric anesthesiologists' preferences for attributes of child daycase surgery: a discrete choice experiment. Paediatric Anaesthesia, 2007, 17, 1043-1052.	1.1	19
68	Women's preferences for the provision of emergency hormonal contraception services. International Journal of Clinical Pharmacy, 2007, 29, 183-189.	1.4	16
69	Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study. International Journal of Clinical Pharmacy, 2007, 29, 661-670.	1.4	15
70	The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. International Journal of Clinical Pharmacy, 2007, 30, 17-23.	1.4	142
71	Strategies for Coping in a Complex World: Adherence Behavior Among Older Adults with Chronic Illness. Journal of General Internal Medicine, 2007, 22, 805-810.	2.6	82
72	Poor Adherence to Anti-inflammatory Medication in Asthma. Disease Management and Health Outcomes, 2006, 14, 223-233.	0.4	18

#	Article	IF	CITATIONS
73	Patient-centred advice is effective in improving adherence to medicines. International Journal of Clinical Pharmacy, 2006, 28, 165-170.	1.4	161
74	Comparing costs of home-versus hospital-based treatment of infections in adults in a specialist cystic fibrosis center. International Journal of Technology Assessment in Health Care, 2005, 21, 506-510.	0.5	13
75	Benefits and Consequences for the Poor and the Disabled. New England Journal of Medicine, 2005, 353, 2739-2741.	27.0	27
76	Cost-Effectiveness of Adherence-Enhancing Interventions: A Quality Assessment of the Evidence. Annals of Pharmacotherapy, 2005, 39, 508-515.	1.9	64
77	The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ: British Medical Journal, 2004, 329, 948.	2.3	203
78	Costing day case anesthesia: obtaining accurate patient-based costs for adults and children. International Journal of Technology Assessment in Health Care, 2004, 20, 552-561.	0.5	3